- Home
- GRNT vs LYEL Comparison
GRNT vs LYEL Comparison
Compare GRNT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$24.34
Company Overview
Basic Information| Metric | GRNT | LYEL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.4M | 504.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRNT | LYEL |
|---|---|---|
| Price | $5.12 | $24.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 548.4K | 89.2K |
| Earning Date | 03-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 8.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $427,828,000.00 | $41,000.00 |
| Revenue This Year | $34.25 | N/A |
| Revenue Next Year | $9.17 | N/A |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | ★ 19.33 | N/A |
| 52 Week Low | $4.18 | $7.65 |
| 52 Week High | $6.72 | $45.00 |
Technical Indicators
Market Signals| Indicator | GRNT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 47.57 |
| Support Level | $4.91 | $21.07 |
| Resistance Level | $5.20 | $26.76 |
| Average True Range (ATR) | 0.16 | 2.00 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 83.89 | 58.70 |
Price Performance
Historical Comparison GRNT
LYEL
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.